CN1221266C - Compound prepn containing alpha-linolic acid, lecithin and ginkgetin - Google Patents
Compound prepn containing alpha-linolic acid, lecithin and ginkgetin Download PDFInfo
- Publication number
- CN1221266C CN1221266C CN 01139971 CN01139971A CN1221266C CN 1221266 C CN1221266 C CN 1221266C CN 01139971 CN01139971 CN 01139971 CN 01139971 A CN01139971 A CN 01139971A CN 1221266 C CN1221266 C CN 1221266C
- Authority
- CN
- China
- Prior art keywords
- alpha
- linolenic acid
- lecithin
- compound formulation
- ginkgetin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a composite preparation which comprises alpha-linolenic acid, phosphatidyl choline, ginkgetin, vitamin E and taurine. The preparation is made into soft capsules, dropping agents or other preparations. The health-care product is used for compensating the insufficiency of the omega-3 fatty acids and phosphatidyl choline in the human body and has the function of strengthening the brain.
Description
The present invention relates to a kind of preparation, be specifically related to a kind of compound formulation that contains alpha-linolenic acid, lecithin and ginkgetin.
Alpha-linolenic acid is called as and maintains the human evolution, keeps one of essential fatty acid of human life activity, is that ω-3 is the parent of a plurality of unsaturated fatty acids, is basic, the most primary core substance in the life evolutionary process.In human brain organ, contain alpha-linolenic acid and metabolite about 30%, also contain a large amount of alpha-linolenic acids and metabolite docosahexenoic acid (DHA) and eicosapentaenoic acid (EPA) in human retina, the nervous system.Alpha-linolenic acid and metabolite DHA and EPA have extremely important physiological function, will cause many organ dysfunction efficient reductions and physiology morbid state occur if human body lacks this class fatty acid.Many studies show that, the sickness rate of modern diseasies such as hypertension, hyperlipidemia, hyperglycemia, coronary heart disease and fatty liver, cancer are risen and are all lacked relevant with alpha-linolenic acid.Simultaneously, the shortage of alpha-linolenic acid can influence the albocinereous growth of brain, causes the generation of nervous organ's function, visual organ deterioration and senile dementia.
1993, FAO (Food and Agriculture Organization of the United Nation) and World Health Organization (WHO) united and issue a statement: in view of the importance and the human situation that generally lacks of alpha-linolenic acid, and worldwide special alpha-linolenic acid and the metabolite thereof promoted of decision.
October 26 calendar year 2001, Beijing Youth Daily's published article, along with aged tendency of population and aging, senile dementia will become one of 21 century threat the most serious human disease, and in the U.S., the senile dementia death toll accounts for the 4th of old people's cause of the death.10% dementia of suffering from is in various degree arranged among China 1.3 hundred million old men approximately, have a strong impact on old people's health.Though the cause of disease of senile dementia is also not clear, strengthen the nutrition and health care of cerebral tissue, to reducing and delay some effects that have of senile dementia, alpha-linolenic acid then is the important nutrient of old people's brain-strengthening.
Lecithin is the important component that constitutes cell membrane, and content is very high in brain cell.To strengthening function of brain cell, improve the brain vigor, promote nerve conduction, promote lipid metabolism, improving blood circulation, effectively prevent and improve the cardiovascular and cerebrovascular disease that hyperlipidemia causes important effect is arranged, be recommended as one of essential nutrient that replenishes every day by the United States Federal's food and drug control committee (FDA).
Ginkgetin can be expanded cardiovascular and cerebrovascular vessel, increases arterial vascular elasticity and permeability, improves cerebral blood flow, improves the brain blood circulation, and functional central nervous system injury is had obvious repair function, is one of important nutrient of brain health care.
The present invention is exactly the brain strengthening function according to alpha-linolenic acid, lecithin and ginkgetin, prepares a kind of compound oral formulations that contains alpha-linolenic acid, lecithin, ginkgetin, vitamin E, taurine and medicinal or edible adjuvant.
Compound formulation involved in the present invention contains alpha-linolenic acid 20%～50%.Wherein alpha-linolenic acid is by the seed oil (perilla oil of purified labiate Folium Perillae, contain alpha-linolenic acid 55%～70%) or linaceous linen seed oil (Semen Lini oil, contain alpha-linolenic acid 40%～60%), or spissated alpha-linolenic acid oil (content 〉=70%) enters preparation.
Compound formulation involved in the present invention contains ginkgetin, and ginkgetin is provided by Folium Ginkgo extract, accounts for 5%～10% in prescription.Ginkgo total flavones content 〉=24% in the Folium Ginkgo extract, bilobalide content 〉=6%.
Compound formulation involved in the present invention contains lecithin 30%～10%, and wherein lecithin is food stage or pharmaceutical grade, is provided by refining soybean lecithin, and purity is more than 98%.
Compound formulation involved in the present invention also contains vitamin E and taurine, and the two all has protective effect to brain cell, and vitamin E is also as antioxidant.
Compound formulation involved in the present invention also contains edible or pharmaceutic adjuvant, as Polyethylene Glycol, gelatin, glycerol, deionized water etc.
Compound formulation involved in the present invention can be the form of gelatin soft capsule; every capsules content 300mg～1000mg; every capsules contains alpha-linolenic acid 100mg～400mg; contain lecithin 50mg～300mg; Folium Ginkgo extract 25mg～100mg; vitamin E 3～10mg and taurine 8～16mg, other right amount of auxiliary materials.
The preparation method of compound formulation involved in the present invention is as follows: Folium Ginkgo extract is sneaked in the liquid macrogol of 4～8 times of amounts; stir; adding the oils and fats, lecithin, taurine, the vitamin E that contain alpha-linolenic acid then in proportion fully mixes; with colloid mill or the abundant homogenizing of homogenizer; then according to the soft capsule preparation method; utilize gelatin, glycerol to be capsule wall, make soft capsule, also can be made into drop or other dosage forms.
Following example is used to illustrate the present invention, but should not be considered as restriction of the present invention.
Embodiment one:
Take by weighing: perilla oil (containing alpha-linolenic acid 60%) 400g
Powdery lecithin (purity 98%) 200g
Folium Ginkgo extract 50g
VE 100g
Taurine 110g
PEG400 100g
Folium Ginkgo extract is joined in the PEG400; stir; be sequentially added into the abundant mixing of perilla oil, vitamin E, lecithin and taurine then; make it temperature maintenance at 15～25 ℃; homogenizing is once under cooling condition then; mixed liquor is placed in the storage tank of encapsulating machine, make 1200 gelatin soft capsules.Every heavy 800mg of soft capsule content contains alpha-linolenic acid 200mg, lecithin 166mg, Folium Ginkgo extract 44mg.
Embodiment two:
Take by weighing: oleum lini (containing alpha-linolenic acid acid 50%) 600g
Lecithin (purity 98%) 200g
Folium Ginkgo extract 40g
Vitamin E 100g
Taurine 40g
Polyethylene Glycol 60g
In Polyethylene Glycol, order adds oleum lini, vitamin E, lecithin and taurine with the outstanding breast of Folium Ginkgo extract, stirs, with the colloid mill homogenizing once.Make 1300 capsules then, every soft capsule content 800mg contains alpha-linolenic acid 288mg, lecithin 192mg, Folium Ginkgo flavone 38mg.
Embodiment three:
Take by weighing: molecular distillation alpha-linolenic acid oil (alpha-linolenic acid content 70%) 360g
Lecithin 240g
Vitamin E 100g
Folium Ginkgo extract 60g
Polyethylene Glycol 80g
Folium Ginkgo extract is suspended in the Polyethylene Glycol stirs, order adds alpha-linolenic acid oil, vitamin E and lecithin powder, abundant mix homogeneously, use the homogenizer homogenizing, make 1200 gelatin soft capsules then, the tolerant heavy 420mg of every intragranular contains alpha-linolenic acid 150mg, lecithin 120mg, Folium Ginkgo extract 30mg.
Claims (3)
1, a kind of alpha-linolenic acid that contains, the compound formulation of lecithin and Folium Ginkgo extract, it is characterized in that, said preparation contains the following composition of percentage by weight, alpha-linolenic acid 20%-50%, lecithin 10%-30%, Folium Ginkgo extract 5%-10%, wherein said alpha-linolenic acid is by perilla oil, Semen Lini oil or molecular distillation alpha-linolenic acid oil are as the raw material of preparation, described perilla oil contains alpha-linolenic acid 55%～70%, Semen Lini oil contains alpha-linolenic acid 40%～60%, molecular distillation alpha-linolenic acid oil contains alpha-linolenic acid 70%, and wherein said lecithin is by the raw material of refining soybean lecithin as preparation.
According to the compound formulation of claim 1, it is characterized in that 2, this compound formulation also contains a certain amount of vitamin E, taurine, Polyethylene Glycol, gelatin, glycerol and deionized water.
According to the compound formulation of claim 1, it is characterized in that 3, the dosage form of this compound formulation is gelatin soft capsule or drop.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01139971 CN1221266C (en) | 2001-11-22 | 2001-11-22 | Compound prepn containing alpha-linolic acid, lecithin and ginkgetin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01139971 CN1221266C (en) | 2001-11-22 | 2001-11-22 | Compound prepn containing alpha-linolic acid, lecithin and ginkgetin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1421208A CN1421208A (en) | 2003-06-04 |
| CN1221266C true CN1221266C (en) | 2005-10-05 |
Family
ID=4675561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01139971 Expired - Fee Related CN1221266C (en) | 2001-11-22 | 2001-11-22 | Compound prepn containing alpha-linolic acid, lecithin and ginkgetin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1221266C (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308007C (en) * | 2003-08-26 | 2007-04-04 | 贲晓明 | Cerebrum nurishment intensification prescription |
| US7501136B2 (en) * | 2003-09-30 | 2009-03-10 | Kao Corporation | Deodorant composition |
| CN101637481B (en) * | 2009-08-05 | 2012-07-11 | 北京双鹤高科天然药物有限责任公司 | Prescription of gingkgo leaf soft capsule and preparation method thereof |
| CN102018823A (en) * | 2009-09-17 | 2011-04-20 | 上海泰佳生物科技有限公司 | Composite preparation containing phospholipid, alpha-linolenic acid, gamma-linolenic acid and tomato extract |
| CN103844271A (en) * | 2012-12-06 | 2014-06-11 | 孙天民 | Nutritive combination agent capable of preventing and treating dementia |
| CN104721264A (en) * | 2013-12-23 | 2015-06-24 | 无锡伟康生物科技有限公司 | Soft capsule with auxiliary effect of reducing blood sugar |
| CN104116078B (en) * | 2014-06-30 | 2016-02-10 | 山东省农业可持续发展研究所 | A kind of peony seed oil voltage stabilizing fat reducing health product |
| CN104304646A (en) * | 2014-10-21 | 2015-01-28 | 宣城柏维力生物工程有限公司 | Lecithin soft capsules and preparation method thereof |
| CN107927732A (en) * | 2017-12-15 | 2018-04-20 | 浙江中医药大学 | It is a kind of to prevent depressed and senile dementia health food and preparation method thereof |
| CN108902937B (en) * | 2018-06-11 | 2021-08-27 | 湖州维义生物科技股份有限公司 | Functional food for preventing senile dementia and preparation method thereof |
| CN111248439A (en) * | 2020-03-31 | 2020-06-09 | 唯思敦食品(上海)有限公司 | Health food for preventing and adjunctively treating Alzheimer's disease and preparation method thereof |
-
2001
- 2001-11-22 CN CN 01139971 patent/CN1221266C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1421208A (en) | 2003-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0347056B1 (en) | Essential fatty acid compositions | |
| JP2810916B2 (en) | Pharmaceutical compositions containing fatty acids | |
| EP1390025B1 (en) | Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders | |
| DE60132081T2 (en) | PREPARATION FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASES | |
| DE3486235T2 (en) | Fatty acid compositions. | |
| ES2202454T3 (en) | USE OF A BALANCING AGENT FOR OMEGA-3 AND OMEGA-6 Unsaturated FATTY ACIDS. | |
| CN1221266C (en) | Compound prepn containing alpha-linolic acid, lecithin and ginkgetin | |
| JPH06128154A (en) | Food composition | |
| US10857108B2 (en) | Composition for preventing and/or treating cardiovascular and cerebrovascular diseases | |
| WO1994005319A1 (en) | Brain function ameliorant composition, learning capacity enhancer, mnemonic agent, dementia preventive, dementia curative, or functional food with brain function ameliorant effect | |
| EP0729753A1 (en) | Agents for treatment or prevention of hypertension and related symptons and disorders; their preparation and use | |
| CN1104252C (en) | Health-care oil for reducing cholesterol and its preparing process | |
| CN101797270B (en) | Silkworm pupal oil fat emulsion intravenous fluid and preparation method | |
| CN107372861B (en) | Composition and application thereof in preparation of product for improving hyperlipidemia | |
| DE4012894C2 (en) | Pharmaceutical agent for the treatment of disorders of the fat metabolism | |
| CN1228057C (en) | Compound of solanesol and its preparing process | |
| CN1618308A (en) | Soybean ovolecithin capsule | |
| CN102631370A (en) | Composition for preventing or improving hyperlipidemia and supplementing vitamin D | |
| CN1298698A (en) | Health-care oil for regulating blood fat | |
| CN102018763A (en) | Linseed oil fat emulsion intravenous injection fluid and production method thereof | |
| KR940000004B1 (en) | Pharmaceutical preparation containing alpha-linolenic acid used for liver disease | |
| WO2020069695A1 (en) | Nutrition-based support for the body's own wound healing processes | |
| WO1993015729A1 (en) | Side-effect alleviant | |
| AU2002255167B2 (en) | Coenzyme Q and eicosapentaenoic acid (EPA) | |
| US20170042947A1 (en) | Unsaturated fatty acid absorption accelerator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051005 Termination date: 20121122 |